View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 13, 2016

Lilly and Boehringer to evaluate combination drug in Phase Ib breast cancer trial

Eli Lilly and Company (LLY) and Boehringer Ingelheim will collaborate on the Phase Ib trial to evaluate the combination of abemaciclib (LY2835219) and BI 836845 to treat metastatic breast cancer.

Eli Lilly and Company (LLY) and Boehringer Ingelheim will collaborate on the Phase Ib trial to evaluate the combination of abemaciclib (LY2835219) and BI 836845 to treat metastatic breast cancer.

Lilly's abemaciclib (LY2835219) is an investigational, orally-administered product that inhibits cyclin-dependent kinases CDK 4 and CDK 6, thereby preventing the growth of cancer cells.

Boehringer's BI 836845 is an antibody that neutralises insulin-like growth factor (IGF)-1 / IGF-2 ligand.

Lilly oncology product development and medical affairs senior vice-president Richard Gaynor said: "We are pleased to join with Boehringer Ingelheim to study the potential of their molecule in combination with Lilly's abemaciclib, for which we have an active Phase III development programme underway.

"For patients living with metastatic breast cancer, the limited treatment options available make this an important area of focus for our efforts to advance the most innovative treatments."

"For patients living with metastatic breast cancer, the limited treatment options available make this an important area of focus for our efforts to advance the most innovative treatments."

While abemaciclib blocks CDK 4 and CDK 6 from triggering the growth of cancerous cells, BI 836845 binds to both IGF-1 and IGF-2, subsequently blocking activation of the respective receptor and resulting in decreased growth-promoting signalling, which may inhibit tumour growth.

The combination of abemaciclib and BI 836845 is expected to offer a complete pathway interference and inhibit growth of the cancerous cell cycle.

Subject to the Phase Ib trial results, the companies are intending to initiate Phase II trials of the combination for patients with HR+, HER2- metastatic breast cancer (mBC) and other solid tumours.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena